GlycA Linked to Insulin Sensitivity, Independent of CRP

Share this content:
GlycA Linked to Insulin Sensitivity, Independent of CRP
GlycA Linked to Insulin Sensitivity, Independent of CRP

FRIDAY, Jan. 6, 2017 (HealthDay News) -- N-acetylglucosamine/galactosamine (GlycA) is associated with insulin sensitivity, independent of C-reactive protein (CRP), according to a study published online Dec. 28 in Diabetes Care.

Carlos Lorenzo, M.D., from the University of Texas Health Science Center in San Antonio, and colleagues conducted cross-sectional analyses involving 1,225 participants with and without type 2 diabetes in the Insulin Resistance Atherosclerosis Study. The authors examined the relation of GlycA, sialic acid (GlycB), and CRP to direct measures of insulin sensitivity (insulin sensitivity index [SI]) and insulin secretion (acute insulin response [AIR]).

The researchers observed a strong correlation for GlycA and GlycB with CRP (both P < 0.001). In a linear regression model with both GlycA and CRP as independent variables, there was an independent association for GlycA and CRP with SI, even after adjustment for demographics, smoking, physical activity, plasma glucose, and body mass index. There was no independent correlation for CRP or GlycA with AIR.

"GlycA may complement CRP in evaluating the relationship between inflammation, glucose tolerance, and insulin resistance," the authors write.

One author is employed by Eli Lilly and Company.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »